Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) plans to issue a Notice of Funding Opportunity (NOFO) to support translational and clinical research focused on pregnant women, lactating women, infants, children, and adolescents. The aim is to advance precision medicine by developing novel tools, models, and therapeutics; improving drug safety and efficacy; enhancing patient‑provider communication; and scaling evidence‑based interventions. The solicitation is part of the Best Pharmaceuticals for Children Act (BPCA) and PRGLAC initiatives. Applications are not being solicited at this time; the forecast indicates an anticipated posting in early 2027 with a submission deadline of July 9, 2027 and award expected April 1, 2028. Eligible applicants include a wide range of public, private, tribal, and nonprofit entities. Funding will be provided via a grant mechanism. • Focus: translational research in maternal, pediatric, and adolescent pharmacology and therapeutics. • Objectives: develop precision‑medicine tools, novel therapeutics, safety communication strategies, and implementation/scaling of interventions. • Funding instrument: NIH grant (likely R01‑type or similar). • Anticipated timeline: posting ≈ Mar 2027, application deadline ≈ Jul 2027, award ≈ Apr 2028, project start ≈ Apr 2028. • Eligible applicants: state, local, tribal governments, higher‑education institutions, for‑profit and nonprofit organizations, foreign entities, etc. • No specific award ceiling/floor disclosed; typical NIH translational grants range from several hundred thousand to a few million dollars over multiple years.